Increased therapeutic efficacy of combination of azithromycin and ceftazidime on  biofilm in an animal model of ureteral stent infection by unknown
RESEARCH ARTICLE Open Access
Increased therapeutic efficacy of
combination of azithromycin and
ceftazidime on Pseudomonas aeruginosa
biofilm in an animal model of ureteral stent
infection
Xianfeng Wang, Yongqing Cai, Haiyan Xing, Wei Wu, Guanying Wang, Ling Li and Jianhong Chen*
Abstract
Background: Infection caused by ureteral stent indwelling is one of the most difficult medical problems, since
once bacteria reside in biofilms they are extremely resistant to antibiotics as well as to the host immune defences.
In this study we assessed the in vitro and in vivo efficacy of azithromycin and ceftazidime in preventing ureteral
stent infection by Pseudomonas aeruginosa.
Results: The susceptibility testing with adherent bacteria showed that the biofilm was strongly inhibited by azithromycin
treatment, ceftazidime against adherent bacteria in the presence of azithromycin showed the minimum inhibitory
concentrations (MICs) and minimum bacteriocidal concentrations (MBCs) dramatically lower than those obtained in the
absence of azithromycin. Moreover, ceftazidime plus azithromycin reduced twitching motility and production of
rhamnolipid. For the single-treatment groups, in vivo intravenous injection of ceftazidime showed the highest inhibitory
effect on bacterial load. Azithromycin prophylactic injection combined with ceftazidime showed increased inhibitory
effect on bacterial load than that of each single antibiotic.
Conclusions: Combination of azithromycin and ceftazidime effectively prevent the formation of biofilm and reduced
bacteria load of Pseudomonas aeruginosa compared to separate treatment of either of these two antibiotics. This
combined treatment option have the potential to contribute to the success of Pseudomonas biofilm elimination in the
clinical environment.
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Background
Ureteral stents are a basic study tool in Urology. They are
widely used for treatment of urolithiasis and relief of
benign or malignant obstruction [1, 2]. However, when
the medical devices was implanted in the urinary tract
they can provide conditions for biofilm formation. The
longer devices remain indwelling, the greater the probabil-
ity of bacteria to develop biofilms [1]. Biofilm formation
increased the infection risk, morbidity, and encrustation
that may result in renal failure and even death [3–5].
Pseudomonas aeruginosa is an opportunistic human
pathogen frequently linked to infections of indwelling
catheters and foreign-body implants [6, 7]. Its biofilm is
equiped with an exopolysaccharide matrix that is able to
adhere to various biotic and abiotic surfaces [3, 8, 9].
When P. aeruginosa have colonized ureteral stent, it is
almost impossible to deracinate the biofilm, which in-
crease virulence factors with immune evasion and anti-
biotic resistance [10, 11]. To eradicate the infection,
surgery is necessary to remove the implant but the re-
placement has a tendency of bacterial recolonization
that results in renal insufficiency [6, 10].* Correspondence: chenjh-110@263.net
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Biofilm formation is controlled by a system of bacterial
intercommunication, known as quorum sensing (QS).
The importance of QS in the pathogenesis of P. aerugi-
nosa infection has gained considerable attention in de-
veloping antimicrobial strategy [12–14]. When P.
aeruginosa generate biofilms, the QS-controlled produc-
tion of tissue-damaging virulence factors such as rham-
nolipid can kill incoming polymorphonuclear leucocytes
(PMNs), which enhance biofilm formation by release of
PMN DNA [15]. The high morbidity and mortality and
resistance to conventional antimicrobial drugs in
Pseudomonas-related biofilm infection needs new urgent
therapeutic strategies. The potential clinical value of
antibacterial agents that control P. aeruginosa infection
by impeding QS and adhesion abilities has recently been
emphasized. Biofilm models in vitro and in vivo have
been utilized to access the susceptibility of P. aeruginosa
to antimicrobial agents [16–18].
Azithromycin (AZM) has shown potential inhibiting
effects on P. aeruginosa biofilm with reducing of bac-
teria virulence factors and adhesion abilities when it was
used in sub-inhibitory concentrations in a urinary tract
infection (UTI) and cystic fibrosis (CF) model [19, 20].
Ceftazidime (CAZ) also showed QS inhibitory activity,
decreasing the production of a range of QS-regulated
virulence factors [21]. In the present study, we assessed
the in vitro and in vivo potential of AZM and CAZ in
preventing ureteral stent biofilm infection induced by a
clinical isolate of mucoid P. aeruginosa. The experiments
were performed using Checkerboard technique to test
the in vitro synergistic antimicrobial effects of AZM and
CAZ and ureteral stent biofilm infection model to evalu-




The development of adherent biofilm was photometrically
corroborated when the bacterial strain showed a mean
OD570 nm of 0.786 ± 0.058. CAZ against the adherent
bacteria without AZM showed MIC and MBC values of
128.00 and 512.00 mg/L, respectively. CAZ plus AZM
showed MICs 16-fold (8.00 mg/L) and MBCs 32-fold
(32.00 mg/L) lower (Table 1).
Synergy studies
In the interaction studies between CAZ and AZM, syn-
ergy was confirmed when the range of FIC indexs was
0.192–0.429 in five clinically isolated strains (Table 2).
Effect on twitching motility
P.aeruginosa possesses type IV pili, which enable the
organism to recruit adjacent cells through twitching
motility and form biofilm [22]. The result indicated that
CAZ didn’t reduce twitching motility of P.aeruginosa,
but combination of CAZ and AZM significantly reduced
twitching motility compared to CAZ or AZM (P < 0.01,
P < 0.01) (Table 3, Fig. 1).
Inhibition of rhamnolipid production in vitro
Rhamnolipid as an important tissue-damaging virulence
factor can enhance formation of biofilm and protect the
biofilm from host immune defense [15]. The result
showed that CAZ or AZM significant inhibited produc-
tion of rhamnolipid compared to no antibiotic (P < 0.05,
P < 0.01). Moreover, combination of CAZ and AZM sig-
nificantly reduced production of rhamnolipid compared
to CAZ or AZM (P < 0.01, P < 0.05) (Fig. 2).
In vivo studies
The findings that synergistic activity of AZM and CAZ
was noted in in vitro studies encouraged us to conduct
combination therapy in an animal model of P. aeruginosa
stent biofilm infection. The result showed that none of the
animals suffered from stent infection in the control group
(C0) without bacterial challenge. In contrast, all rats suf-
fered from graft infection in challenged control group
(C1), with quantifying value showing 6.85 ± 0.602 log10
cfu/mL. Rats that treated with CAZ showed stent bacterial
counts of 3.58 ± 0.274 log10 cfu/mL. Rats that prophylac-
tically treated with AZM showed stent bacterial counts of
4.96 ± 0.438 log10 cfu/mL. Interestingly, CAZ combined
with AZM showed efficacies higher than that of each sin-
gle drug, without a presence of bacterial counts (P < 0.001)
(Fig. 3). Similarly, urine cultures were negative in both con-
trol group (C0) and combined therapy group. Urine
cultures results also showed that a significant reduction in
Table 1 Antimicrobial activity of CAZ and AZM against adherent
cells of clinical isolate of P. aeruginosa
Agent AH165 slime-producing strain (adherent cells)
MIC (mg/L) MBC (mg/L)
AZM >256 >256
CAZ 128 512
AZM plus CAZa 8 32
aWells pre-treated with AZM (8 mg/L AZM in MH broth for 30 min)
Table 2 Results of combination of CAZ and AZM






The range of drug dilutions used was 0.25–256 mg/L. FIC indexes were
interpreted as ≤ 0.5, synergy; 0.5–4.0, indifferent; and >4.0, antagonism
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log count of 4.49 ± 0.403 and 5.77 ± 0.518 in the groups of
rats treated intravenously respectively with CAZ and AZM,
as compared with 6.78 ± 0.586 in the challenged control
group (C1)(P < 0.001) (Fig. 4). Drug related adverse effects
and dead rats were not observed in any group throughout
the study.
Discussion
Infection caused by ureteral stent indwelling is one of
the most difficult medical problems, since once bacteria
reside in biofilms they are up to 1000-fold more tolerant
to antibiotics. Moreover, ureteral stent infection can not
be easily diagnosed. It is reported that 90 % indwelling
silicone double J stents were occupied by adherent bac-
teria; however, only 27 % of urinary infection was clinic-
ally detected [23]. It is also reported that only 30 % of
stent indwelling patients were found to have bacteriuria,
but 68 % were found stent colonization [24]. An add-
itional problem in ureteral stent biofilm associated in-
fections is the development of encrustation and
consecutive obstruction [6, 7]. Biofilm that contribute
to antibiotic resistance has a variety of attributes, such
as, a mixed population of rapidly and slow- or non-
growing bacteria, an exopolysaccharide matrix, a
change in gene expression [25]. Biofilm of bacterial
colonization also acts as a physical barrier against host
defense [26, 27]. As biofilms are increasingly resistant
to antibiotics, making monotherapy ineffective, combin-
ation therapy is essential for eradication of infection [28].
The aim of the present study was to assess the efficacy
of AZM and CAZ (an anti-Pseudomonas agent) in pre-
venting ureteral stent-associated Pseudomonas infection.
We hypothesize that AZM might inhibit the virulence
factors of the bacteria by preventing initial adherence to
the implants or biofilm formation thereby enhance the
activity of CAZ. Our data showed that both AZM and
CAZ significantly reduced bacterial load on ureteral
stent tissue. When AZM was combined with CAZ, no
evidence of Pseudomonas was detected on the stent or
in the urine. In vitro studies also demonstrated that
AZM enhanced the effect of CAZ against some
Pseudomonas strains, in accordance with reported
results. Moreover, CAZ plus AZM reduced twitching
motility and production of rhamnolipid.
In fact, although AZM has no antimicrobial activity
against P. aeruginosa at therapeutic concentrations, our
study showed that AZM may exert activity against this
microorganisms. It can exert its effect on P. aeruginosa
biofilm formation by reducing bacterial virulence factors
at sub-inhibitory concentrations and influencing the flux
of 3-oxo-C12-HSL through changed membrane perme-
ability [29]. It has also been reported that AZM is able
to reduce IV pili-confered twitching motility which con-
tributes to bacterial adherence and generation of biofilm
[20]. CAZ is a third generation cephalosporin effective
against Gram-negative bacteria especially P. aeruginosa
and also a QS-inhibitor [21, 30], but it is insensitive to
P. aeruginosa in adherent form [28]. In the combination,
AZM has augmented the activity of CAZ in vitro [28],
but the in vivo efficacy has never been validated. We
exteneded the study to an in vivo P. aeruginosa ureteral
stent biofilm model. The doseage levels and the delivery
method of CAZ and AZM used in this study are based
on reported studies methods which mimic clinical practice
[20, 31]. Results suggest that AZM was effective in
Table 3 Effect on twitching motility
Drug Zone diameters(cm)
control 1.16 ± 0.050
CAZ 1.15 ± 0.047
AZM 0.62 ± 0.036a
CAZ + AZM 0.34 ± 0.021a,b,c
aStatistically significant when compared with no antibiotic treated medium(control),
P< 0.01
bStatistically significant when compared with singly CAZ-treated medium, P< 0.01
cStatistically significant when compared with singly AZM-treated medium, P < 0.01
Fig. 1 Demonstration of twitching motility of P. aeruginosa (AH165). Detailed legend: control- no antibiotic, CAZ- Ceftazidime,AZM- azithromycin
Wang et al. BMC Microbiology  (2016) 16:124 Page 3 of 8
preventing biofilm formation, and combined with CAZ, it
was able to improve CAZ activity through reduction of
bacterial adherence and virulence factor production.
Therefore, our investigation indicates that injection intra-
venous of AZM prophylactically is able to prevent biofilm
formation through reducing bacterial adherence and viru-
lence factor production. Subsequect intravenous injection
of CAZ after implantation aids to the clearance of P.
aeruginosa.
Conclusions
In conclusion, prevention of P. aeruginosa bioflim for-
mation and reduction of bacteria load of Pseudomonas
aeruginosa was enhanced by CAZ combined with AZM
compared to separate treatment of either of these two
antibiotics. Combination therapy of azithromycin and
ceftazidime have the potential to contribute to the success
of Pseudomonas biofilm elimination in the clinical
environment.
Fig. 2 Inhibition of production rhamnolipid of P. aeruginosa (AH165). Detailed legend: The concentration of rhamnolipid in the untreated culture was set
equal to an index value of 100. The graph is based on the average of the indexes of three independent experiments. *P< 0.05; *** P< 0.001 (compared
with control); ### P< 0.001 (compared with CAZ); △P< 0.05 (compared with AZM)
Fig. 3 Activity of CAZ and AZM against P. aeruginosa (AH165) clinical isolate in a rat model of ureteral stent infection (stent cutrue). Detailed legend:
Ureteral stents were explanted at day 5 following implantation. Bacterial counts are given in terms of log10 cfu/mL. The limit of detection for the method
was ≤1 cfu/mL. *** P< 0.001 (compared with control); ### P< 0.001 (compared with CAZ); △△△P< 0.05 (compared with AZM)
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Methods
Bacterial strains
Five clinical isolates of P. aeruginosa were collected from
urine samples of patients having catheter-associated UTI
attending the Institute of Surgery Research, Daping Hos-
pital, Third Military Medical University, Chongqing,
China. This study protocol was approved by the Ethics
Committee in Research of Institute of Surgery Research,
Daping Hospital, Third Military Medical University. A
mucoid strain of P. aeruginosa (AH165) was used in this
study, another four strains were used for interaction stud-
ies. All strains were stocked in 10 % glycerol at −80 °C.
Antimicrobial agents
Sterile stock solution of azithromycin (AZM) (Sigma-Al-
drich, USA) and ceftazidime (CAZ) (Sigma-Aldrich,
USA) was prepared according to the manufactures’ in-
structions and stored at −80 °C. Working solutions were
prepared in Mueller-Hinton broth at 512 mg/L for
CAZ,8192 mg/L for AZM. These working solutions were
serial 2-fold diluted with Mueller-Hinton broth and dis-
tributed in a 96-well microtiter plate. The antibiotic dos-
ages of CAZ and AZM used in the in vivo experiments
were 100 mg/kg and 350 mg/kg, respectively [20, 31].
Susceptibility testing with planktonic bacteria
MICs and MBCs were determined by broth microdilu-
tion using the 2-fold dilution method according to CLSI
guidelines [32]. The antibiotic concentrations tested
ranged from 0.5 to 256 mg/L for CAZ and from 2 to
4096 mg/L for AZM.
Biofilm-forming capacity
Biofilm-forming capacity was determined as previously
described [22]. Prior to testing, the strains were subcul-
tured in tryptic soy broth (TSB) (Sigma Fluka, USA) and
incubated overnight after retrieval from −80 °C. A bac-
terial suspension in TSB was prepared with an inoculum
density equivalent to 106 cfu/mL. Afterwards, 50 μL of
TSB were inoculated into each well of polystyrene 96-
well microtiter plate (Corning, USA) containing 150 μL
of TSB/2 % glucose. The growth medium was discarded
after 24 h of incubation at 37 °C, and then each well was
washed three times with sterile PBS to remove free cells.
The remaining attached bacteria were fixed for 15 min
with 200 μL of 99 % methanol per well, and the wells
were emptied and left to dry. Wells were then stained
with 0.2 mL of Crystal Violet (2 %, w/v) for 5 min at
room temperature. Excess dye was removed by washing
the well with running tap water. The plates were air
dried and the dye taken up by the biofilm cells was
extracted with 0.2 mL of glacial acetic acid (33 %, v/v)
per well. Absorbance was measured at 570 nm by using
Multiskan Spectrum (Thermo Scientific, Finland). The
same experiment was performed three times with and
without the addition of 8 mg of AZM in Mueller-Hinton
(MH) broth in each well. Biofilm capacity was calculated
as three standard deviations above the mean OD of the
negative control.
Susceptibility testing with adherent bacteria
The MIC and MBC were determined with modifications
for use in the biofilm test. Biofilms were washed with
Fig. 4 Activity of CAZ and AZM against P. aeruginosa (AH165) clinical isolate in a rat model of ureteral stent infection (urine cutrue). Detailed legend:
The urine cultures were performed 24 h after ureter stent placement using a transvesical sample taken by an insulin syringe. Bacterial counts are given
in terms of log10 cfu/mL. The limit of detection for the method was ≤10 cfu/mL. *** P < 0.001 (compared with control);
### P < 0.001 (compared with
CAZ); △△△P < 0.05 (compared with AZM)
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sterile PBS in order to remove non-binding cells. Subse-
quently, 200 μL of MH broth containing serial 2-fold
dilutions of antibiotic were added to each well of tissue-
culture-treated polystyrene 96-well microtiter plate con-
taining adherent organisms. The plates were incubated
for 18 h at 37 °C in air. The MIC was taken as the lowest
CAZ concentration at which observable growth was
inhibited. To determine the MBC, the MH broth con-
taining CAZ was removed from each well and replaced
with antibiotic-free MH broth; the plates were incubated
again for 18 h at 37 °C in air. The MBC was taken as the
lowest concentration of AZM that resulted in no bacterial
growth following removal of the drug. In addition, to
investigated the effect of AZM pre-treatment on bacterial
susceptibility to CAZ, the MIC and MBC of CAZ were
again determined after pre-treatment of cells by incuba-
tion for 30 min at room temperature in 8 mg/L AZM
solution immediately before susceptibility testing.
Twitching motility assay
Twitching motility was assayed on freshly prepared
Luria-Bertani agar plates (1 % Bacto agar) containing
medium with 4 mg/L CAZ, 8 mg/L AZM, 4 mg/L CAZ
plus 8 mg/L AZM, or no antibiotic (control) [20]. For
the motility assay, organisms were grown overnight and
stabbed with a sterile toothpick through the agar layer
to the bottom of the Petri dish. The plates were incu-
bated at 37 °C for 48 h and washed gently with tap water
to remove any unattached cells. Then the attached cells
were stained with crystal violet (0.1 %,W/V). The diam-
eter of the stained zone was measured to assess the
twiching motility.
Quantification of rhamnolipid
Rhamnolipid B was measured with an Agilent 1100
series high-pressure liquid chromatography connected to
a Micromass LCT time-of-flight mass spectrometer. The
total ionization current was determined on the [M+NH4]
+
ion at 668.4 over the 7 s over which rhamnolipid B was
eluted. Before determination of rhamnolipid B, P. aerugi-
nosa (AH165) cultures were grown to an OD600 of 2.0 with
4 mg/L CAZ, 8 mg/L AZM, 4 mg/L CAZ plus 8 mg/L
AZM, or no antibiotic (control). Cells were harvested by
centrifugation, and the supernatants were filter sterilized
(TPP syringe filter; pore size, 0.22 μm). The concentration
of rhamnolipid in the untreated culture was set equal to an
index value of 100.
Synergy studies
To test the antibiotic combinations of AZM and CAZ,
five clinical isolate strains were used in the studies.
Checkerboard arrangements of AZM and CAZ were
prepared in 96-well polypropylene microtitre plates. In
the Checkerboard technique, two drugs are compared in
microtitre wells the drug concentrations equal to,
above, and below the MIC of the drugs being tested.
The fractional inhibitory concentration (FIC) index
for combinations of two antimicrobials was calculated
as follows [33, 34]:
FIC of CAZ FICAð Þ ¼ MIC of CAZ in combination=MIC of CAZ alone;
FIC of AZM FICBð Þ ¼ MIC of AZM in combination=MIC of AZM alone:
The sum of fractional inhibitory concentration (FICs)
indices of two compounds in the combination was calcu-
lated as follows:
FICA þ FICB ¼ FICs
Synergism = FICs ≤ 0.5; antagonist = FICs ≥ 4; additive =
FICs > 0.5 and ≤ 1; indifference = 1 < FICs < 4.
Animals
Adult female Wistar rats (weight range 190–240 g) were
provided by Center for Experimental Animals of Third
Military Medical University (Chongqing, China) and
were maintained on standard rat chow and water ad
libitum before the challenge. The animal studies were
carried out in accordance with the guidelines for the
Ethical Treatment of Laboratory Animals. All proce-
dures of rat care and handling were in accordance with
accepted standard operating procedures of the Third
Military Medical University. Animals study was
approved by the Animal Care and Utilization Committee
of the Third Military Medical University.
Ureteral stent infecion model
Rats were randomly divided into five groups including a
control group (C0) without bacterial challenge to evaluate
the sterility of the surgical procedure, a challenged control
group (C1) that did not receive any antibiotic prophylaxis,
and three challenged groups that received intravenous
CAZ 100 mg/kg immediately after stent implantation;
intravenous AZM 350 mg/kg prophylactically before im-
plantation; and intravenous CAZ plus intravenous AZM at
the above concentrations. Each group contained ten rats.
Ureteral stent implants were prepared as described previ-
ously by Daniele Minardi et al. [35] with some modifica-
tions. Rats were anaesthetized by an intramuscular
injection of ketamine and xylazine (30 mg/kg and 8 mg/kg,
respectively), then sterile ureteral stent implants with a size
of 0.2 cm2 (Porges-Mentor, France) were used and inserted
into the bladder. Before stent implantation, some of rats
were injected intravenously with 350 mg/kg AZM once
every 24 h from day 2 pre-insertion to day 5 post-insertion;
After the surgical intervention, a saline solution (1 mL)
containing 2 × 107 cfu/mL of Pseudomonas strain was inoc-
ulated into the bladder using a tuberculin syringe. After
stent implantation, some of the animals received
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intravenous CAZ immediately once every 24 h until to day
5 post-insertion. On the basis of previous experiments
demonstrating peak bacterial growth and biofilm formation
within 72 h [36], all ureteral stents were explanted at day 5
following implantation. Toxicity was evaluated on the basis
of the presence of any drug related adverse effects, i.e.
anorexia, weight loss, fever, vomiting, diarrhea, behavioral
alterations and local signs of local inflammation.
Assessment of the infection
To verify sterility or infection of rats, urine cultures were
performed through a transvesical sample taken by an
insulin syringe 24 h after ureteral stent placement. The
explanted ureteral stents were washed in sterile saline
solution and sonicated for 2 min in phosphate-buffered
saline solution to remove the adherent bacteria from the
grafts. After the ultrasound treatment, 100 μL of the
PBS-bacteria solution was serial diluted and plated on
McConkey agar plates. The plates were incubated at 37 °C
for 48 h before determination of cfu per implant. The limit
of detection for this method was approximately 10 cfu/mL.
Statistical analysis
Values of MIC and MBC are presented as the geometric
mean of three separate experiments. To compare the bac-
teria counts (log10 cfu) between groups of rats in in vivo
experiments, quantitative culture results were presented as
mean ± S.D and Tukey–Kramer Honestly Significant Differ-
ence Test was used for calculating P value. Significance was
accepted when the P value was 0.05.
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